Empirical Financial Services LLC d.b.a. Empirical Wealth Management Makes New Investment in Inhibrx, Inc. (NASDAQ:INBX)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 22,584 shares of the company’s stock, valued at approximately $348,000.

Separately, Exchange Traded Concepts LLC bought a new position in Inhibrx in the fourth quarter valued at about $148,000. 82.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Inhibrx

In related news, Director Jon Faiz Kayyem bought 69,686 shares of Inhibrx stock in a transaction on Tuesday, November 19th. The shares were purchased at an average price of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the acquisition, the director now owns 51,093 shares in the company, valued at approximately $727,053.39. This represents a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 22.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Stock Up 0.6 %

Shares of INBX stock opened at $12.31 on Thursday. The firm’s 50 day moving average price is $14.54 and its two-hundred day moving average price is $14.66. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $18.95.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.